Patents by Inventor Junxing Shi
Junxing Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250114389Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.Type: ApplicationFiled: April 11, 2022Publication date: April 10, 2025Inventors: Raymond SCHINAZI, Franck AMBLARD, Mahesh KASTHURI, Nicolas BITEAU, Junxing SHI, Longhu ZHOU, Keivan ZANDI
-
Patent number: 9932326Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: GrantFiled: November 10, 2015Date of Patent: April 3, 2018Assignees: Cocrystal Pharma, LLC, Emory UniversityInventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Patent number: 9926295Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: GrantFiled: April 15, 2015Date of Patent: March 27, 2018Assignees: Cocrystal Pharma, Inc., Emory UniversityInventors: Steven J. Coats, Richard Anthony Whitaker, Tamara Rosario McBrayer, Junxing Shi, Franck Amblard, Hongwang Zhang, Longhu Zhou, Raymond F. Schinazi
-
Patent number: 9861652Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 6, 2015Date of Patent: January 9, 2018Assignees: Emory University, The University of Georgia Research Foundation, Inc.Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Publication number: 20170029407Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: ApplicationFiled: April 15, 2016Publication date: February 2, 2017Inventors: Steven J. Coats, Richard Anthony Whitaker, Tamara Rosario McBrayer, Junxing Shi, Franck Amblard, Hongwang Zhang, Longhu Zhou, Raymond F. Schinazi
-
Patent number: 9382286Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.Type: GrantFiled: December 4, 2013Date of Patent: July 5, 2016Assignees: EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
-
Publication number: 20160158266Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 6, 2015Publication date: June 9, 2016Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Publication number: 20160068518Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: ApplicationFiled: November 10, 2015Publication date: March 10, 2016Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Patent number: 9180138Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 2, 2012Date of Patent: November 10, 2015Assignees: University of Georgia Research Foundation, Inc., Emory UniversityInventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Patent number: 9181227Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: GrantFiled: August 8, 2014Date of Patent: November 10, 2015Assignees: Cocrystal Pharma, Inc., Emory UniversityInventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Publication number: 20140350016Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Patent number: 8895531Abstract: The present invention includes compounds and compositions of ®-2?-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.Type: GrantFiled: March 22, 2007Date of Patent: November 25, 2014Assignee: RFS Pharma LLCInventor: Junxing Shi
-
Publication number: 20140336143Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.Type: ApplicationFiled: December 4, 2013Publication date: November 13, 2014Applicants: GILEAD PHARMASSET LLC, BETH ISRAEL DEACONESS MEDICAL CENTER, EMORY UNIVERSITYInventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
-
Patent number: 8859595Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: GrantFiled: August 26, 2011Date of Patent: October 14, 2014Assignees: RFS Pharma, LLC, Emory UniversityInventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Publication number: 20130210774Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.Type: ApplicationFiled: August 26, 2011Publication date: August 15, 2013Applicants: EMORY UNIVERSITY, RFS PHARMA, LLCInventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
-
Patent number: 8481713Abstract: The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.Type: GrantFiled: May 25, 2010Date of Patent: July 9, 2013Assignee: Gilead Pharmasset LLCInventors: Peiyuan Wang, Wojciech Stec, Byoung Kwon Chun, Junxing Shi, Jinfa Du
-
Publication number: 20120202766Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.Type: ApplicationFiled: February 13, 2012Publication date: August 9, 2012Applicant: Pharmasset, Inc.Inventors: Michael J. Otto, Junxing Shi, Kyoichi A. Watanabe
-
Patent number: 8168583Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 27, 2009Date of Patent: May 1, 2012Assignees: University of Georgia Research Foundation, Inc., Emory UniversityInventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Patent number: 8114997Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.Type: GrantFiled: January 4, 2008Date of Patent: February 14, 2012Assignee: Pharmasset, Inc.Inventors: Michael J. Otto, Junxing Shi, Kyoichi A. Watanabe
-
Patent number: RE42015Abstract: The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.Type: GrantFiled: June 21, 2007Date of Patent: December 28, 2010Assignee: Pharmasset, Inc.Inventors: Kyoichi A. Watanabe, Junxing Shi, Michael J. Otto